Skip to main content

Cybin Inc(CYBN-A)
NYSE Arca

Today's Change
Delayed Last Update
Day Low8.14
Day High8.38
Open:8.27
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Tipranks
Helus Pharma Rebrands, Moves to Nasdaq as It Advances Late-Stage Mental Health Drugs
Business Wire
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq
Tipranks
Cybin Launches US$100 Million At-the-Market Equity Program
Tipranks
Cybin Sets Up US$100 Million At-the-Market Equity Program With Cantor Fitzgerald
Business Wire
Cybin Initiates At-The-Market Equity Program of up to US$100 Million
Tipranks
Cybin to Rebrand as Helus Pharma and Shift U.S. Listing to Nasdaq in Early January
Tipranks
Cybin (CYBN) Receives a Buy from H.C. Wainwright
Tipranks
Cybin to Rebrand as Helus Pharma and Shift U.S. Listing to Nasdaq
Tipranks
Cybin to Rebrand as Helus Pharma and Shift U.S. Listing to Nasdaq
Business Wire
Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq
Tipranks
Cybin Secures $175 Million in Direct Offering to Advance Clinical Programs
Tipranks
Alliance Global Partners Reaffirms Their Buy Rating on Cybin (CYBN)
Tipranks
Analysts’ Top Healthcare Picks: Serina Therapeutics (SER), Cybin (CYBN)
Tipranks
Cybin, Inc. Navigates Progress and Challenges in Earnings Call
Tipranks
Cybin Inc. Advances Clinical Trials with Strong Financial Backing
Tipranks
Cybin to Present at Jefferies Global Healthcare Conference
Business Wire
Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights
Business Wire
Cybin to Participate in the Jefferies Global Healthcare Conference in London
Tipranks
Cybin to Release Q2 Financial Results and Business Update
Tipranks
Cybin to Engage in Healthcare Innovation Conference
Business Wire
Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025
Business Wire
Cybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
Tipranks
Cybin’s CMO to Join Panel at 2025 Milken Institute Health Summit
Business Wire
Cybin to Participate at the 2025 Milken Institute Future of Health Summit
Tipranks
Cybin Secures $175 Million in Direct Offering to Boost Mental Health Initiatives
Business Wire
Cybin Announces Closing of $175 Million Registered Direct Offering
Tipranks
Cybin Inc. Secures $175 Million in Direct Offering to Fund Clinical Programs
Business Wire
Cybin Announces $175 Million Registered Direct Offering
Tipranks
Cantor Fitzgerald Keeps Their Buy Rating on Cybin (CYBN)
Tipranks
Cybin Advances Clinical Programs in Psychedelic Therapeutics
Tipranks
H.C. Wainwright Reaffirms Their Buy Rating on Cybin (CYBN)
Business Wire
Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones

Profile

Cybin Inc. is a biotechnology company. It is focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. Cybin Inc. is based in Toronto, Canada.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.